TY - JOUR
T1 - Genetic and nongenetic factors for contralateral progression of unilateral moyamoya disease
T2 - the first report from the SUPRA Japan Study Group
AU - the SUPRA Japan Study Group
AU - Mineharu, Yohei
AU - Takagi, Yasushi
AU - Koizumi, Akio
AU - Morimoto, Takaaki
AU - Funaki, Takeshi
AU - Hishikawa, Tomohito
AU - Araki, Yoshio
AU - Hasegawa, Hitoshi
AU - Takahashi, Jun C.
AU - Kuroda, Satoshi
AU - Houkin, Kiyohiro
AU - Miyamoto, Susumu
AU - Date, Isao
AU - Wakabayashi, Toshihiko
AU - Muraoka, Shinsuke
AU - Uda, Kenji
AU - Fujii, Yukihiko
AU - Kikuchi, Bunpei
AU - Kataoka, Hiroharu
AU - Hamano, Eika
AU - Kashiwazaki, Daina
AU - Kurisu, Kaoru
AU - Okazaki, Takahito
AU - Ishii, Taizo
AU - Iwama, Toru
AU - Tomoi, Miyuki
AU - Nakase, Hiroyuki
AU - Hironaka, Yasuo
AU - Yamada, Shuichi
AU - Iihara, Koji
AU - Nishimura, Ataru
AU - Matsushima, Toshio
AU - Enomoto, Toshiyuki
AU - Tanaka, Hideaki
AU - Kazumata, Ken
AU - Uchino, Haruto
AU - Toukairin, Kikutaro
AU - Nagahiro, Shinji
AU - Satomi, Junichiro
AU - Kanematsu, Yasuhisa
AU - Ohtomo, Etsuko
AU - Mikuni, Nobuhiro
AU - Mikami, Tsuyoshi
AU - Ogasawara, Kuniaki
AU - Chida, Kohei
AU - Saito, Nobuto
AU - Miyawaki, Satoru
AU - Morioka, Motohiro
AU - Morita, Satoshi
AU - Kosugi, Shinji
N1 - Funding Information:
We thank the following members of the SUPRA Japan Study Group for their efforts in patient recruitment: Okayama University (Dr. Isao Date), Nagoya University (Dr. Toshihiko Wakabayashi, Dr. Shinsuke Muraoka, and Dr. Kenji Uda), Niigata University (Dr. Yukihiko Fujii and Dr. Bunpei Kikuchi), National Cerebral and Cardiovascular Research Center (Dr. Hiroharu Kataoka and Dr. Eika Hamano), Toyama University (Dr. Daina Kashiwazaki), Hiroshima University (Dr. Kaoru Kurisu, Dr. Takahito Okazaki, and Dr. Taizo Ishii), Gifu University (Dr. Toru Iwama and Ms. Miyuki Tomoi), Nara Medical University (Dr. Hiroyuki Nakase, Dr. Yasuo Hironaka, and Dr. Shuichi Yamada), Kyushu University (Dr. Koji Iihara and Dr. Ataru Nishimura), Fukuoka Sannou Hospital (Dr. Toshio Matsushima, Dr. Toshiyuki Enomoto, and Dr. Hideaki Tanaka), Hokkaido University (Dr. Ken Kazumata, Dr. Haruto Uchino, and Dr. Kikutaro Toukairin), Tokushima University (Dr. Shinji Nagahiro, Dr. Junichiro Satomi, Dr. Yasuhisa Kanematsu, and Dr. Etsuko Ohtomo), Sapporo Medical University (Dr. Nobuhiro Mikuni and Dr. Tsuyoshi Mikami), Iwate Medical University (Dr. Kuniaki Ogasawara and Dr. Kohei Chida), University of Tokyo (Dr. Nobuto Saito and Dr. Satoru Miyawaki) and Kurume University (Dr. Motohiro Morioka). Statistical analyses were checked by Dr. Satoshi Morita. The ethical issues were double-checked by Dr. Shinji Kosugi. This study was supported by Grants in Aid for Scientific Research (B) to S.M. (nos. 16H05437 and 19H03770), a Grant in Aid for Scientific Research (A) to A.K. (no. 25253047), and a Grant in Aid for Young Scientists (B) to Y.M. (no. 15K19963).
Publisher Copyright:
© AANS 2022
PY - 2022/4
Y1 - 2022/4
N2 - OBJECTIVE Although many studies have analyzed risk factors for contralateral progression in unilateral moyamoya disease, they have not been fully elucidated. The aim of this study was to examine whether genetic factors as well as nongenetic factors are involved in the contralateral progression. METHODS The authors performed a multicenter cohort study in which 93 cases with unilateral moyamoya disease were retrospectively reviewed. The demographic features, RNF213 R4810K mutation, lifestyle factors such as smoking and drinking, past medical history, and angiographic findings were analyzed. A Cox proportional hazards model was used to find risk factors for contralateral progression. RESULTS Contralateral progression was observed in 24.7% of cases during a mean follow-up period of 72.2 months. Clinical characteristics were not significantly different between 67 patients with the R4810K mutation and those without it. Cox regression analysis showed that the R4810K mutation (hazard ratio [HR] 4.64, p = 0.044), childhood onset (HR 7.21, p < 0.001), male sex (HR 2.85, p = 0.023), and daily alcohol drinking (HR 4.25, p = 0.034) were independent risk factors for contralateral progression. CONCLUSIONS These results indicate that both genetic and nongenetic factors are associated with contralateral progression of unilateral moyamoya disease. The findings would serve to help us better understand the pathophysiology of moyamoya disease and to manage patients more appropriately.
AB - OBJECTIVE Although many studies have analyzed risk factors for contralateral progression in unilateral moyamoya disease, they have not been fully elucidated. The aim of this study was to examine whether genetic factors as well as nongenetic factors are involved in the contralateral progression. METHODS The authors performed a multicenter cohort study in which 93 cases with unilateral moyamoya disease were retrospectively reviewed. The demographic features, RNF213 R4810K mutation, lifestyle factors such as smoking and drinking, past medical history, and angiographic findings were analyzed. A Cox proportional hazards model was used to find risk factors for contralateral progression. RESULTS Contralateral progression was observed in 24.7% of cases during a mean follow-up period of 72.2 months. Clinical characteristics were not significantly different between 67 patients with the R4810K mutation and those without it. Cox regression analysis showed that the R4810K mutation (hazard ratio [HR] 4.64, p = 0.044), childhood onset (HR 7.21, p < 0.001), male sex (HR 2.85, p = 0.023), and daily alcohol drinking (HR 4.25, p = 0.034) were independent risk factors for contralateral progression. CONCLUSIONS These results indicate that both genetic and nongenetic factors are associated with contralateral progression of unilateral moyamoya disease. The findings would serve to help us better understand the pathophysiology of moyamoya disease and to manage patients more appropriately.
KW - alcohol
KW - genetics
KW - moyamoya
KW - progression
KW - risk factor
KW - RNF213
KW - unilateral
KW - vascular disorders
UR - http://www.scopus.com/inward/record.url?scp=85128160913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128160913&partnerID=8YFLogxK
U2 - 10.3171/2021.3.JNS203913
DO - 10.3171/2021.3.JNS203913
M3 - Article
C2 - 34507293
AN - SCOPUS:85128160913
SN - 0022-3085
VL - 136
SP - 1005
EP - 1014
JO - Journal of neurosurgery
JF - Journal of neurosurgery
IS - 4
ER -